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Pesticides and Neurologic
Symptoms 
We read with interest the recent study titled
“Neurologic Symptoms in Licensed Private
Pesticide Applicators in the Agricultural
Health Study” (Kamel et al. 2005). Although
this was a hypothesis-generating study, the
authors speculated regarding moderate expo-
sure and associations with neurologic symp-
toms. Substantiation of hypotheses requires
meaningful metrics of exposure and effect,
and depends on exclusion and analysis of
competing hypotheses for the observations.
In our opinion, the article by Kamel et al.
falls seriously short in several regards and
requires additional data in order to provide
credible and defensible conclusions. 
Kamel et al. (2005) analyzed a number of
symptoms in those “ever” experiencing one of
23 self-reported symptoms in the preceding
12 months. The biologic significance of the
outcome “symptom count” is unknown; also,
“multiple symptoms” is not a definable dis-
ease or illness. The fact that private applica-
tors report headache, nausea, and fatigue does
not establish that each is of neurologic origin,
particularly given the physical requirements
of farming. Indeed, results of the questions
used by Kamel et al. (2005) have been shown
to agree poorly with objective tests of neuro-
logic function (Lundberg et al. 1997).
Further, Kamel et al. limited the analyses to a
single episode rather than symptoms that
were reported more than once per year
(Kamel et al. (2005); Table 2). As a cross-
sectional analysis, the data do not permit
assessment of the temporal relationship
between exposure and symptom onset, and
no consideration was given to the transient
nature of the reported symptoms. Thus,
although the nature of the analysis implies
some sort of persistent neurologic condition
underlying the reporting of symptoms, no
such condition can be established from
intermittent symptoms of indeterminate
etiology. 
In addition to other potential causes for
these symptoms, researchers have warned
about the role of psychosocial factors in the
reporting of non-specific symptoms.
According to Spurgeon et al. (1996),
Many occupational and environmental health
hazards present as an increased reporting of non-
specific symptoms such as headache, backache,
eye and respiratory irritation, tiredness, memory
problems, and poor concentration. The pattern
and number of such symptoms is surprisingly
constant from hazard to hazard suggesting that
common psychological and social factors, not
directly related to the exposure may be involved.
The role of these factors has been well
documented in the psychological literature.
Such factors include attitudes and belief sys-
tems; current or preexisting stress; workers’
perception of the competence and credibil-
ity of management; and involvement of the
media, pressure groups, and the legal system
(Spurgeon et al. 1997). Further, “[p]reven-
tion and control strategies are unlikely to be
successful if the real sources of the problems
are not correctly identified” (Spurgeon et al.
1997). 
Because Kamel et al. (2005) relied on
self-reported days of application to infer
exposure rather than actual measured dose,
their assumption of sufficient exposure to
cause a biologic effect has severe limitations.
The Agricultural Health Study (AHS) has
used lifetime exposure days for specific, indi-
vidual pesticides in other publications
(Alavanja et al. 2003, 2004; Engel et al.
2005), but Kamel et al. (2005) offered no
support for their change in approach and the
validity of a class-wide, rather than pesticide-
specific biologic effect. Furthermore, studies
indicate that farmers have much less pesti-
cide exposure than is often assumed from
self-reported use and even within this low
range; the exposure is variable for a given
day. For example, in a study of organo-
phosphate applicators, Stokes et al. (1995)
identified differences in urinary metabolite
levels based on the number of tanks loaded,
acres sprayed, and hours sprayed. Other bio-
monitoring studies have identified a large
range of exposure for different pesticides,
including applicators with no detectable
exposure (Arbuckle et al. 2002; Mandel et al.
2005). The exposure metric used by Kamel
et al. (2005) of cumulative lifetime days
applied most likely overestimates exposur, in
light of these exposure studies of farmer
applicators. 
We believe that the findings of Kamel
et al. (2005) may well be the result of evalu-
ating multiple pesticides as groups at a time
in conjunction with other physical or emo-
tional stress related to farming or even a
common ailment such as influenza (Dunn
et al. 1995). In any event, the conclusions
are not justified by the data because there is
no coherent disease outcome and no mean-
ingful exposure metric. It is our view that
even hypotheses generated by such non-
specific data do not meet the stated AHS
objective, which is to “provide information
that agricultural workers can use in making
decisions about their health and the health
of their families” (AHS 2005).
Both authors are employed by companies that
manufacture pesticides.
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Pesticides and Neurologic
Symptoms: Kamel et al. Respond
Burns and Goldstein raise several issues
regarding our paper (Kamel et al. 2005), in
which we reported that applicators chroni-
cally exposed to moderate levels of pesticide
experience more neurologic symptoms. They
assert that our measures of exposure and
effect are not “meaningful.” We disagree. 
Burns and Goldstein state that “‘multi-
ple symptoms’ is not a definable disease or
illness.” Although this is true, symptoms
cause many medical visits and so are signifi-
cant to public health. Further, we made no
claim that applicators reporting more symp-
toms had a particular disease. Indeed, in
some of our analyses we purposely excluded
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order to evaluate associations of pesticide
use specifically with symptoms. We studied
a mixed group of symptoms, all sometimes
associated with neurologic dysfunction or
disease, although with varying specificity.
Excluding two relatively nonspecific symp-
toms (headache and fatigue) did not appre-
ciably change the distribution of the
symptom variable. The assertion that we
limited our analysis to ”a single episode” is
inaccurate: our main analyses evaluated
multiple rather than single symptoms, and
we took symptom frequency into account
in our analysis of individual symptoms
(Kamel et al. 2005; Table 4). We acknowl-
edged the limitations of cross-sectional
analysis in our article. However, the associa-
tions we observed were with cumulative
pesticide use; accounting for recent use did
not change results. 
The issue is not whether the symptoms
we studied are diagnostic of neurologic or
other disease, but whether experiencing these
symptoms is associated with pesticide expo-
sure. Burns and Goldstein cite Lundberg
et al. (1997) but omit Lundberg et al.’s con-
clusion that the exposure-related relationship
of symptom reporting to organic solvent
exposure makes this approach useful for
comparing groups with different exposures.
At least 23 previous studies used symptom
reporting to evaluate neurologic effects of
pesticide exposure, with 19 reporting posi-
tive associations (Kamel and Hoppin 2004).
We extended this approach to a very large
group of applicators who had detailed expo-
sure information available.
Burns and Goldstein discuss potential fac-
tors related to symptoms, citing Spurgeon’s
biopsychosocial model (Spurgeon et al.
1996). We agree that personal and social fac-
tors likely influence both experience and
reporting of symptoms. However, Spurgeon
(2002) noted that 
Discussion of the determinants of symptom
reporting does not constitute a dismissal of the
farmer’s illness but simply a recognition that it is
likely to result from a complex interaction of
physical, psychological, and social processes.
She described a study of farmers whose
symptoms were associated with five factors,
one being handling sheep within 48 hr of
pesticide dipping. Thus, pesticide exposure
may still be associated with increased symp-
toms even (or perhaps especially) when
psychosocial factors are taken into account.
Most of the factors Burns and Goldstein list
are unlikely to be related to exposure in
licensed applicators and so cannot explain
the associations seen. Further, confounding
by psychosocial factors would likely produce
associations with all types of pesticides, but
our findings were specific to insecticides.
Finally, we do not understand Burn’s and
Goldstein’s comment that our findings are
“the result … of a common ailment such as
influenza”; are they suggesting that pesti-
cide exposure is associated with increased
risk of flu? 
Burns and Goldstein call our exposure
measures limited, citing biomonitoring
studies which show that variations in inter-
nal exposure are not completely correlated
with external exposure. This point is largely
irrelevant because the associations seen
depend not on identifying the absolute level
of pesticide exposure but rather on ranking
applicators as relatively more or less exposed.
Variation in the degree to which self-
reported days of use represents internal
exposure is probably nondifferential with
respect to symptom reporting, with resulting
misclassification likely to bias associations
towards the null; the true relationship may
be stronger than we observed. Our findings
of associations with insecticides only, and
with cumulative but not recent exposure,
suggest that recall bias does not fully
account for our results. We see no problem
in combining pesticides for a class-wide
analysis, particularly because many grouped
pesticides exert effects through similar or
related biologic mechanisms. Using class-
wide analyses may minimize confounding
because most applicators used multiple pes-
ticides. Ultimately, it will be interesting to
evaluate the effects of individual chemicals;
we are planning such studies. 
Thus, our measures of both exposure
and effect are sufficient for their purpose,
which is to examine the association of
symptom reporting with moderate insecti-
cide exposure. Our study clearly demon-
strates such an association. Importantly, it is
independent of both recent exposure and a
history of high exposure or poisoning, sug-
gesting that lifetime exposure at moderate
levels may have health consequences. This
finding has implications for farmers’ health
and deserves to be reported and evaluated
further. 
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Tungsten Alloy and Cancer in
Rats: Link to Childhood
Leukemia?
We read with interest the article by Kalinich
et al. (2005) on the generation of rhabdo-
myosarcomas from “embedded weapons-
grade tungsten alloy.” Although the study
design and the reported findings are of great
interest, we are concerned about certain
statements made in both the “Introduction”
and the “Discussion” of the article. In these
sections the authors make reference to the
allegation that “several cancer clusters in the
United States are associated with elevated
levels of tungsten in the environment”
(Kalinich et al. 2005) Although they accu-
rately point out that “no definitive link …
has been established,” they suggest that the
cancer clusters are part of “a growing list of
health concerns related to tungsten expo-
sure.” However, the conditions at Fallon,
Nevada, and the investigations into a pur-
ported link between naturally occurring
tungsten and childhood leukemia are very
different from the experimental conditions
that exist in the implantation study by
Kalinich et al. (2005).
The Centers for Disease Control and
Prevention (CDC) conducted a thorough
investigation into the Fallon cancer cluster; in
fact, it was the largest cancer cluster investiga-
tion ever undertaken in the United States.
The scientists from the CDC and state health
departments concluded that exposure to
tungsten was not associated with the inci-
dence of childhood leukemia in Fallon (CDC
2003). The genesis of the leukemia cases is
still an area of interest and speculation as
shown by a recent letter in EHP (Daughton
2005). Because Kalinich et al. (2005) inferred
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Fallon leukemias while presenting data sug-
gesting that implanted tungsten alloy caused
metastatic tumor formation, readers may
confuse the issues and assume that somehow
the two effects (rhabdomyosarcoma and
childhood leukemia) are related.
We are not questioning the quality of
the work presented by Kalinich et al.
(2005) or their finding that implanted pel-
lets of a specific combination of tungsten/
nickel/cobalt alloy caused an apparent
increase in rhabdomyosarcoma with sub-
sequent metastasis to the lung. Rather, we
recommend that the authors remain
focused on this finding. Suggesting that
these results can be linked to, or somehow
shed light on, childhood leukemia and
exposure to environmental tungsten is both
inappropriate and misleading.
The author provides consulting sevices for
Kennametal, Inc., a company with a facility in
Fallon, Nevada.
John D. Schell
Blasland, Bouck & Lee, Inc.
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Tungsten Alloy and Cancer in
Rats: Kalinich Responds
We would like to address Schell’s com-
ments about our article published in EHP
(Kalinich et al. 2005). Schell expresses con-
cern about certain statements we made in
our article about embedded tungsten alloy
fragments, especially our reference to the
undisputed Centers for Disease Control
and Prevention (CDC) finding that there is
an increased incidence of childhood
leukemia in areas where there are high levels
of environmental tungsten (CDC 2003;
Sheppard and Witten 2004). Schell con-
tends that our results showing the carcino-
genic potential of embedded tungsten alloy
fragments have no bearing on the situation
in Fallon, Nevada, and believes that our
mentioning them “is both inappropriate
and misleading.” We respectfully disagree.
In our article (Kalinich et al. 2005) we
report an unexpected response in rats to
tungsten alloys that could not have been pre-
dicted by looking at tungsten toxicity alone.
We suggested that our results support the
advisability for further consideration of tung-
sten compounds or synergistic effects of
tungsten with other environmental factors in
cases such as Fallon. We cited several reports
in support of such a view. Miller et al. (2001,
2002) indicated that the presence of tung-
sten in an in vitro model system increased
the toxicity of both nickel and cobalt in a
synergistic manner. Wei et al. (1985, 1987)
reported that tungsten exhibited a promot-
ing effect on N-nitroso-N-methylurea–
induced mammary carcinogenesis in rats.
Other investigators have also suggested the
cause for the Fallon cancer cluster might be
an as yet uninvestigated factor or the result of
simultaneous or sequential exposure to one
or more agents (Daughton 2005). 
At this time it is not clear whether these
similar findings from diverse research are an
unrelated coincidence or whether they sug-
gest a toxicologic property of tungsten not
yet understood. What is clear, however, is
the need for further research in this area,
not only a toxicologic assessment of tung-
sten alone but also potential synergistic
interactions with known toxic agents. The
currently proposed National Toxicology
Program study of tungsten is an important
first step in resolving these issues. 
The author declares he has no competing
financial interests.
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Synthetic Musk Compounds and
Effects on Human Health?
A recent article by Luckenbach and Epel
(2005) on in vitro observations of inhibitory
properties exhibited by certain nitromusk
and polycyclic musk fragrance ingredients
on mussel cells raised some concerns regard-
ing potential environmental risks and safety
to humans that may be associated with
nitromusk and polycyclic musk compounds.
The Research Institute for Fragrance
Materials would like to address several
points that may help readers more clearly
understand the meaning and context of the
reported research.
The tonnages of musk compounds
reported by Luckenbach and Epel (2005) in
their article (7,000–8,000 tons) are higher
than the industry-reported global tonnage
of these materials. From 1995 to 2000, the
total worldwide usage declined from
300 tons to 200 tons for musk xylene and
musk ketone combined. The 2000 world-
wide use of polycyclic musks is approxi-
mately 4,000 tons.
Measured concentrations of these com-
pounds in the environment are less than
the effects concentrations reported by
Luckenbach and Epel (2005). In a review of
measured environmental concentrations,
Rimkus (1999) stated that the highest
reported measurement of hexahydro-
hexamethyl-cyclopenta (γ)-2-benzopyran
(HHCB) in surface water was 12.5 µg/L
(0.048 µM). The IC50 (concentration that
inhibits 50%) reported for polycyclic musks
was 2.34 µM. Overall, measured environ-
mental concentrations were 2–6 orders of
magnitude lower than the effects concentra-
tions reported by Luckenbach and Epel
(2005).
The data reported by Luckenbach and
Epel (2005) reflect a method under develop-
ment. There are many steps between the
observation of an in vitro effect and effects
on whole organisms, ecosystems, and
humans. In vivo studies in mussels and stud-
ies linking mussel gill tissue to undefined tis-
sues in mammals and humans are some of
the research necessary to conclude that these
higher level effects may exist. These effects
would then need to be placed into a risk-
based context by comparing them to expo-
sure concentrations.
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musk compounds for humans has been
extensively tested and affirmed by numerous
regulatory agencies and academic scientists
around the world [Scientific Committee on
Cosmetic Products and Non-Food Products
(SCCNFP) 2002a, 2002b]. The trace
environmental levels of the musks continue
to be investigated, and environmental safety
and monitoring studies are ongoing so that
the public can be assured of their safety.
Regarding the environmental effects of
synthetic musks, the IC10 (concentration
that inhibits 10%) values should be com-
pared to no observed effect concentrations
(NOECs). The IC10 values of the syn-
thetic musks are around the level of the
lowest in vivo NOECs observed for
aquatic organisms.
Table 1 shows that the in vitro multi-
xenobiotic resistance (MXR) transporter
activity in mussel gill is of the same sensitiv-
ity as the effects observed in the standard
toxicity tests with aquatic organisms. Thus,
at the exposure level where the protective
transporter efflux is decreased, rendering
the cell more accessible to other potential
toxicants, the effects of the synthetic musks
are also indicated in other end points, such
as development and growth.
The observed effects are not limited to
the nitromusk and polycyclic musk com-
pounds.For example, the other chemicals
used by Luckenbach and Epel (2005)—
verapamil and quinidine—also produced
the phenomenon. In the case of verapamil,
the IC10 was reported at 1–2 orders of mag-
nitude below the nitromusks and polycyclic
musks.
I look forward to continued discussions
with the Luckenbach and Epel to deter-
mine the relevance of the results of this
study.
The author is employed by the Research
Institute for Fragrance Materials, a nonprofit
organization that publishes its work in peer-
reviewed literature under the guidance of an
independent scientific panel and receives support
from the private sector.
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Synthetic Musk Compounds:
Luckenbach Responds
In his letter on our recent article in EHP
(Luckenbach and Epel 2005), Salvito raises
important questions about effects of the syn-
thetic musk fragrances regarding a) human
and environmental health effects, b) environ-
mental concentrations of the musks, and
c) uniqueness of inhibition of efflux trans-
porters to the musks, the effect we described
in our article.
a) Regarding health issues, we agree with
Salvito that the available evidence indicates
minimal direct affects of most synthetic
musks on the health of humans and aquatic
organisms. However, our data expand the
definition of toxicity and detrimental effects
to indirect and unanticipated consequences
of these chemicals, even if the chemical itself
might be nontoxic. The major point of our
article (Luckenbach and Epel 2005) was that
the musks inhibit efflux (drug) transporters,
which act as first lines of defense to pump
potentially toxic substances out of cells.
These efflux transporters are ubiquitous and
are found in bacteria, fungi, plants, and ani-
mals, including humans. The transporters
have wide substrate specificity, and this
binding to many compounds can result in
inhibition of activity by competing sub-
strates. As a consequence of transporter inhi-
bition, cells and organisms can therefore
become exposed to toxicants normally kept
out of their cells. 
An unexpected finding was not only
that the musks inhibit these transporters in
marine mussels but that the effect is long-
term and persists up to 24–48 hr after
removal of the musk compounds. These
indirect and long-term toxicity effects are
of particular concern because these chemi-
cals are stable and bioaccumulate; for
example, musk xylene has a half-life of
70 days in human tissue (Riedel and
Dekant 1999).
Effects on human transporters by the
musks cannot be inferred from our results,
but they do point to the possibility of an
interaction, considering the general property
of the transporters to recognize a wide array
of substrates. Therefore—and in light of
accumulation of the musks in human tis-
sue—research is needed to determine if the
musks similarly inhibit the human efflux
transporters, thereby compromising this
defense against toxicants.
b) The musks are of environmental con-
cern because they enter the water column
from incomplete degradation in sewage
plants. We agree with Salvito that the
reported levels in surface waters are extremely
low (picomolar range) but disagree with his
conclusion that such levels indicate that
musks are not a problem. In spite of these
low environmental levels, there is significant
bioaccumulation of these chemicals in tissues
of mussels and fish, and just several months
ago Nakata (2005) reported significant
bioaccumulation in cetaceans. The concen-
trations in aquatic organisms can become
quite high, being on the order of nanograms
per gram fresh weight, which translates to
about 0.1 µM final concentration in tissue
(Nakata 2005; Rimkus 1999; Yamagishi
et al. 1983).
According to Salvito, worldwide pro-
duction of synthetic musks are only about
one-half of the amount we cite. These
lower numbers are even more worrisome
because because this means that the
potency of the musks to bioaccumulate is
even higher.
c) Salvito points out that the inhibition
of transporters is not unique to the musks.
We agree and note that the observed inhibi-
tion of efflux transporter activity by the
musks may be the tip of the iceberg. As
with the musks, there may be many chemi-
cals that by themselves are not toxic but
similarly inhibit the efflux transporters and
thereby expose the organism to normally
excluded toxicants. 
In summary, the available data suggest
that efflux transporter inhibition could be a
significant indirect, negative, and unappreci-
ated effect of environmental chemicals.
Several questions need to be answered: Do
these chemicals inhibit human transporters?
Are there other anthropogenic and natural
products that inhibit these transporters in
aquatic organisms and also in humans?
Should anthropogenic chemicals be screened
for inhibitory activity? If so, should there be
voluntary or governmental regulations to
ensure that such chemicals do not affect the
health of exposed populations through these
indirect actions?
The authors declare they have no competing
financial interests.
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Table 1. Intensity of in vitro MXR transporter activity
in mussel gill. 
IC10) Lowest NOEC
(mg/L) (mg/L
MK 0.14 mmol =  0.041 0.063
MX 0.09 mmol =  0.027 0.056
AHTN 0.35 mmol = 0.090  0.035
HHCB 0.37 mmol = 0.095 0.068
Abbreviations: MK, musk ketone; MX, musk xylene.Till Luckenbach 
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Benefits and Risks of Pesticide
Testing on Humans
In their review of the history of the U.S.
Environmental Protection Agency’s (EPA)
response to the question of human testing
of pesticides, Resnick and Portier (2005)
argued that the benefits of such testing out-
weigh the hazards, and they attempted to
refute claims that human testing is both
unproductive and unethical. We consider
their arguments vague, tendentious, and
essentially incorrect. 
Unanimously passed by both houses of
Congress in 1996, with the support of pes-
ticide manufacturers, pediatricians, and the
environmental community, the Food
Quality Protection Act (FQPA 1996)
added a 10-fold child protective safety fac-
tor in choosing a reference dose to two ear-
lier factors, one employed to accommodate
the difference between animals and humans
and one to accommodate the variance
among adults. The single stimulus behind
the FQPA was the growing evidence of
increased childhood vulnerability, and the
single reason for its unanimous, bipartisan
passage was to protect children. 
The pesticide industry quickly mounted
a two-pronged attack on the U.S. EPA’s new
guidelines and safety factors (U.S. EPA
2000), arguing that children were not more
sensitive than adults. At the same time, they
launched studies in which organophosphate
pesticides were administered to adult “ vol-
unteers.” This was a palpable effort to cir-
cumvent and weaken the 10-fold human/
animal safety factor, and it flouted the intent
of the law to stimulate the generation of data
on the developmental and pediatric toxicity
of pesticides. Resnik and Portier (2005), in a
curious shift of responsibility, indict the
FQPA as a factor in stimulating human stud-
ies with their claim that 
A law that was intended to provide additional
safety protection for children had the unintended
effect of encouraging some companies to test
toxic compounds on human beings to avoid the
regulatory impact of the law.
With few exceptions the U.S. EPA has
failed to use the mandated 10X factor. In
June 2002 the U.S. EPA issued its cumula-
tive assessment of the organophosphate pes-
ticides (OPs), determining that for the
30 OPs reviewed, a 1X safety factor (that is,
no factor) was used for three OPs and one
metabolite, and a 3X reduction was used for
the others (U.S. EPA 2002). At no time was
a 10X factor used, despite the fact that the
U.S. EPA possessed developmental neuro-
toxicity data for only 6 of the 30 OPs at the
time of its assessment 
In 1998 the U.S. EPA convened a special
committee consisting of members of the
Science Advisory Board, the Science Advisory
Panel for pesticides, and outside ethicists to
examine the ethics of human testing. The
committee had two meetings separated by
12 months, and after five drafts, adopted a
report that accepted human testing subject to
rigorous or severe limitations (U.S. EPA
2000). The two pediatricians on the commit-
tee (H.L.N. and R.R.) filed a minority report
that became part of the record because we
objected to procedural and scientific sole-
cisms. Resnik and Portier (2005) did not
mention this report, even though Portier was
a member of that committee.
Resnik and Portier (2005) recognize
that past industry studies are scientifically
unacceptable. They directed their com-
ments to future, yet-to-be-specified studies.
Such studies, they stated, “can be con-
ducted only if they meet strict scientific and
ethical standards and provide public health
or environmental benefits.” Resnik and
Portier (2005) also stated that studies of
adult volunteers “could yield knowledge
about the toxic effects on humans, which
could promote human health” (National
Research Council 2004). The reader is left
to wonder what toxic effects would be bet-
ter understood through human studies, or
what health benefits could accrue from
short-term volunteer studies. Resnik and
Portier (2005) mentioned neither children’s
health nor developmental toxicity. Instead
they proffered the dubious hope that stud-
ies could result in stricter safety standards or
new legislation that could result in reduced
pesticide exposure. In today’s regulatory cli-
mate, this must be considered a slim possi-
bility. Once more the future standards and
laws remain unspecified.
Two major issues in human testing are
the relevance of data obtained from adult
exposure to risk estimates for children, and
the scientific validity of short-term human
studies as predictors of health outcomes such
as neurodevelopmental deficits and carcino-
genesis. It is axiomatic that a study that is
poorly designed and cannot produce valid
conclusions is unethical on this ground alone.
The provenance of the FQPA (1996)
emerged from the growing realization that
children are vastly different from adults and
that the developing organism, while it is
laying down and pruning back neural con-
nections, is much more sensitive to neuro-
toxicants than fully formed organisms.
What could possibly be learned about the
risk to this group from studying the effects
of toxicants on adults? Resnik and Portier
(2005) did not attempt to address this ques-
tion, but the answer is, very little.
One of the critical issues in evaluating the
scientific validity of a study design is statistical
power. On this basis alone human studies
have failed. A study with inadequate power to
find an effect is by definition unethical. This
type of study submits subjects to some risk
while providing no scientific information.
There are roughly 19 million children in the
United States ≤ 5 years of age. If a toxicant
harmed 1 child in 1,000, that would place
19,000 children at risk nationwide. A study
with adequate power to detect an increase in
deficit from 1% to 2% would require 3,017
subjects in each group to yield a power of
0.8, at α = 0.05. Past industry studies with
sample sizes < 50 had about a 3% chance of
finding an effect if it were present. No men-
tion of this power finding was made by
Resnik and Portier (2005), although this was
published by the U.S. EPA Science Advisory
Board/Federal Insecticide, Fungicide, and
Rodenticide Act (FIFRA) Science Advisory
Panel (U.S. EPA 2000) on which Portier
served as a contributing member.
Resnik and Portier’s article (Resnik and
Portier 2005), when examined in light of
specificity, completeness, and relevance to
the health of children, fails on all points. It
asks the reader to accept unspecified studies
on adults as productive of unspecified bene-
fits to human health. The principal toxic
target, the health of children, remains
unspoken and out of awareness.
J.S is employed by environmental nonprofit
organizations with an interest in ensuring that
regulations of toxic chemicals are as health-
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Pesticide Testing on Humans:
Resnick and Portier Respond
In their letter, Needleman et al. suggest that
our arguments regarding the ethics of
human testing of pesticides (Resnik and
Portier 2005) are “vague, tendentious, and
essentially incorrect.” However, they offer
no effective sustained arguments in support
of this conclusion. 
They cite the Food Quality Protection
Act (FQPA 1996) and note that this act led
pesticide companies to sponsor studies in
humans, in part, to avoid an additional
10-fold human safety factor. They then
chastise our article for saying effectively the
same thing. Their next point focuses on
what they view as a U.S. Environmental
Protection Agency (EPA) failure to enforce
the FQPA for organophosphate pesticides,
an issue that has no bearing on the ethical
question of human testing of pesticides.
They claim that we failed to specify exactly
how human studies could benefit society,
but we clearly stated in our article (Resnik
and Portier 2005) that these studies could
promote public health by providing knowl-
edge that may be useful in regulating pesti-
cides. It is the responsibility of the party
sponsoring or conducting a human testing
study to demonstrate the relevance and util-
ity of the proposed study with regard to
human toxicity. 
Needleman et al. contend that we have
missed an important issue—the relevance of
adult testing to children’s risk. This argu-
ment is not relevant to our article because
we focused on human testing of pesticides
on adults, not on children. We seriously
doubt whether testing pesticides on chil-
dren, or on other vulnerable populations,
could ever be justified on ethical grounds. It
is possible that studies of the effects of pesti-
cides on adults could enhance our under-
standing of how pesticides affect children,
but the party(s) sponsoring the study would
need to provide some evidence for this sup-
position. In our article (Resnik and Portier
2005) we argued that there may be some
cases where the public health benefits of
testing pesticides on adults justify imposing
risks on human subjects. We did not argue
that one of the benefits of testing pesticides
on adults is to improve the health of chil-
dren, but we acknowledge that some studies
might have this potential benefit.
We addressed arguments concerning the
statistical power of human studies in our
Supplemental Material, which is available
online (http://ehp.niehs.nih.gov/members/
2005/7720/suppl.pdf). Good statistical
design is one of the key principles that must
be considered in evaluating the acceptability
of human testing, and we acknowledge that
some of the disputed pesticide studies have
been underpowered. It is surprising to us
that Needleman et al. would raise this con-
cern when their key premise is that human
testing of pesticides is never ethical. If testing
of pesticides is never ethical, then statistical
issues, such as sample size, are irrelevant. 
Needleman et al. have confused the
issues relating to the FQPA, 10X safety
factors, and risk assessment with the ques-
tions surrounding human testing of pesti-
cides. We wholeheartedly agree that to
conduct a clinical study in humans for the
sole purpose of keeping a product com-
mercially viable is unethical. They assume
that the only reason why anyone would
develop and conduct human studies of
pesticides is to promote the interests of
pesticide manufacturers. Again, we address
this issue in our Supplemental Material
(http://ehp.niehs.nih.gov/members/
2005/7720/suppl.pdf). 
We argue that a study that benefits pri-
vate industry can be ethical, provided that it
also offers scientific or social benefits. For
example, clinical trials of new drugs benefit
pharmaceutical companies, but they also ben-
efit patients, enhance our understanding of
human disease, and improve public health. 
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Infant Methemoglobinemia:
Causative Factors 
That individually and environmentally
mediated cofactors function in the develop-
ment of infant methemoglobinemia
(iMHG) is not a new finding. Studies cited
by Fewtrell (2004) note these cofactors. In
my work on iMHG, using a nested case–
control study that was not cited by Fewtrell
(2004), I confirmed that cofactors (feeding
practices, individual and infant physiology,
etc.) played a role in the disease status of
populations under study (Zeman 2000;
Zeman et al. 2002a).
Cofactor work completed with Ustyogova
et al. (2002) indicated that in vitro studies
examining exposures below and above the
maximum contaminant limit for nitrate
show impacts to lymphocyte proliferation
and cytokine production with shift in
immune response from a Th 1 lymphocyte
immune status to a Th 2 lymphocyte, indi-
cating possible decreased resistance to patho-
logical states. Could this be another factor in
iMHG? Ustyogova et al. (2002) examined
healthy adults, but the study raises the issue
of the effects of exposure on the developing
immune system of infants. The microbial
status of drinking water for participants in
the case–control study (Bauer et al. 2003),
has been evaluated at the bacterial and para-
site levels (Bauer et al. 2003, Zeman et al.
2005). Findings indicated that most water
was highly contaminated with fecal coli-
forms (0–1,000/100 mL) and protozoan
oocysts (0–84 cysts/L); when the likelihood
of contamination was compared to data on
whether or not an iMHG case had occurred
in the household, no significant relationship
was found. 
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sure–response data are available, but two arti-
cles (Zeman et al. 2002a, 2002b) reporting
on the iMHG case–control study and asso-
ciated exposure assessment to nitrate/nitrite
contradict this. In one of these studies
(Zeman et al. 2002a), a bivariate fit of
nitrate level in well water and nitrite expo-
sure through water and dietary sources
(p = 0.0001) validated the exposure assess-
ment methodology. Table 9 of this article
illustrates the relationship strength under
bivariate test for a variety of risk factors, and
Table 11 provides a multivariate analysis
showing the most predictive factors for this
study population—exposure to drinking
water nitrates, breast-feeding duration, and
lack of vitamin use (Zeman et al. 2002a). By
stratifying these data for bivariate analysis
and comparing the calculated nitrite expo-
sure for each child for low to medium
(< 0.1 mg/kg/day to ≥ 0.1–1.5 mg/kg/day)
and low to high (< 0.1 mg/kg/day to
≥ 1.5 mg/kg/day) exposures, the likelihood
(L) and Pearson (P) calculations show a defi-
nite gradation in effect and significance in
both situations: low to medium (L = 6.574,
p = 0.0103; and P = 4.377, p = 0.0364); low
to high (L = 20.7474, p = 0.0001; and P =
15.605, p = 0.0001). I agree, however, that
no dose–response relationship has been doc-
umented comparing calculated exposure to
measured blood methemoglobin level at the
time of a clinically diagnosed iMHG case.
This would be a gold standard that would
help us to tease out the causative factors of
iMHG and to establish solidly or refute
what looks like, to date, the centrality of the
role of nitrate exposure in the etiology of
iMHG. 
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Infant Methemoglobinemia:
Fewtrell Responds
In her letter, Zeman seems to be objecting
to three points relating my article (Fewtrell
2004): that the role of cofactors is not new,
that her articles were not cited, and that
exposure–response data are available.
First, in my article (Fewtrell 2004) I did
not suggest that the role of cofactors was a
novel discovery, as evidenced by the selec-
tion of articles I cited noting such factors.
Rather, I noted the fact that the role of
cofactors often seems to be overlooked in
some of the literature.
Second, as stated in the conclusion
(Fewtrell 2004), “the study did not set out to
review the role of nitrates in the causation of
methemoglobinemia” nor, by extension, the
role of cofactors; thus the literature citation
was selective.
Finally, I assessed the article by Zeman
et al. (2002) in the literature review for my
study (Fewtrell 2004), but I felt it did not
provide useful drinking water (i.e., exposure)
data related to the level of methemoglobine-
mia in infants (i.e., response data); therefore,
the article by Zeman et al. (2002) was not
cited (although I do consider the new data
presented in Zeman’s letter to be of interest).
Three points that influenced my deci-
sion not to cite the article by Zeman et al.
(2002) are worth noting. First, Zeman
et al.’s Figure 2 shows an apparent relation-
ship between nitrate level in wells (parts per
million) and “nitrate” (this is presumably
nitrite, as described in the figure legend and
Zeman’s letter) exposure in milligrams per
kilogram per day. This was reported to have
a correlation of 0.71, presumably resulting
in a coefficient of determination of 0.50.
However, some reported concentrations are
remarkably high, exceeding 1,000 ppm
nitrate. The reported relationship appears,
visually, to be dependent on a few very high
value(s) for the claimed correlation, making
inference—or application of the functional
relationship—within more usual exposure
levels inappropriate. The data points within
more “usual” elevated exposure ranges (say
< 500 ppm) do not appear to exhibit a clear
correlation between nitrate concentration
(parts per million) in well water and calcu-
lated nitrite intake in milligrams per kilo-
gram per day.
Second, this figure simply claims a corre-
lation between a concentration (i.e., nitrate
in water, parts per million) and a precurser of
the outcome condition (i.e., calculated nitrite
intake, milligrams per kilogram per day), not
the “outcome” of interest I discussed
(Fewtrell 2004). It is unclear how the boiling
of water (which may lead to an increase in
nitrate concentrations) is accounted for in
the relationship presented by Zeman et al.
(2002). The relationship is also likely to be
location specific, being dependent upon local
feeding habits [e.g., level of formula, tea
(chi), vegetables, etc., given to the infant].
Third, Zeman et al. (2002) did not pro-
vide a detailed explanation of how the
dependent variable numerical values in their
Figure 2 were derived, making it difficult to
assess the quality of this information.
The selection of appropriate studies to
include in any global assessment is difficult
and will always be contentious. I hope that
these observations explain my decision not
to cite the article by Zeman et al. (2002).
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Avian Influenza and UV-B
Blocked by Biomass Smoke 
Washam (2005) described various poultry
inoculation strategies being considered for
controlling the spread of avian influenza in
Southeast Asia and China. Longini et al.
(2005) proposed that a future avian
influenza A pandemic might be contained at
the source by targeted prophylaxis, quaran-
tine, and prevaccination.
Washam (2005) correctly noted that
“Asian farmers, though, are running out of
options.” I propose a new option: Avian
influenza might be controlled by a substantial
reduction in regional scale biomass smoke in
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Southeast Asia that will allow natural solar
ultraviolet-B radiation (UV-B) to suppress
the virus before infection occurs.
Influenza viruses and various non-
pigmented bacteria are killed by UV-B
wavelengths in sunlight (Hollaender and
Oliphant 1944). Biomass smoke signifi-
cantly suppresses natural levels of UV-B,
and severe smoke pollution reduced UV-B
by up to 95% during the burning seasons in
Brazil in 1995 (Mims 1996) and 1997
(Mims FM III, White B, unpublished data).
Reduced UV-B on 6 days in August 1997
was well correlated (r2 = 0.83) with an
increase in the ratio of nonpigmented bacte-
ria vulnerable to UV-B to pigmented bacte-
ria that are protected from UV-B (Mims
and White 1998). Although airborne
influenza viruses were not measured, 1997
hospital admission records at Alta Floresta,
Brazil, showed that influenza incidence
was highest during the burning season
(de Castro GC, personal communication).
Human cases of avian influenza in
Thailand and Vietnam peaked during the
winter burning seasons of 2003 and 2004
(Thailand Ministry of Public Health 2005).
Assuming similar optical properties of bio-
mass smoke in Southeast Asia and Brazil,
where UV-B and optical depth are highly
correlated, optical depth measurements over
Thailand and Vietnam by NASA’s Terra and
Aqua satellites suggest highly suppressed UV-
B during these avian influenza outbreaks
(Mims FM III, unpublished data). 
Human cases of avian influenza in
Thailand and Vietnam since December 2003
have peaked during both the rainy season
and the burning season. Thus, periods of
prolonged cloudiness and severe smoke pol-
lution could play a role in initiating avian
and other influenza outbreaks by attenuating
the solar UV-B that might otherwise sup-
press influenza viruses in outdoor air exposed
to sunlight. The transmission of avian
influenza to people during these periods is
enhanced by the fact that poultry raised for
human consumption are often kept within
several meters of where people live (World
Health Organization 2004). 
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ERRATA
There was an error in Figure 2 of Zeman
et al. [Environ Health Perspect 110:817–822
(2002)]: the y-axis should have been labeled
“Nitrite” instead of “Nitrate.” The corrected
figure appears below. 
In Giusi et al. [Environ Health Perspect
113:1522–1529 (2005)], the colors were
incorrect in the key to Figure 1. The cor-
rected figure appears below. 
EHP regrets the errors.
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